Metrics as of 10/16/2026, 08:34 AM (Berlin time), refresh in progress.
Xilio Therapeutics Stock
Xilio Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Rene Russo
- Employees
- 76
- Market cap
- $59 M
- IPO
- 22/10/2021
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for…
Xilio Therapeutics stock: price history
1D
+1.3%
1W
+0.1%
1M
-0.1%
6M
+8.0%
YTD
+0.7%
1Y
-18.4%
2Y
-19.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~50% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Xilio Therapeutics
Analyst assessment of Xilio Therapeutics
PRICE TARGET LOW
US$98.00
CONSENSUS
US$98.00
MEDIAN
US$98.00
PRICE TARGET HIGH
US$98.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 08/11/2024
Xilio Therapeutics stock metrics
P/E
-6.05
P/B
2.42
EV/EBITDA
3.43
RETURN ON EQUITY
-8.8%
NET MARGIN
-34.1%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
35.8%
FLOAT SHARES
2,357,412
AVG. DAILY VOLUME (30D)
9,716
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Xilio Therapeutics stock
What does Xilio Therapeutics do?
Xilio Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Rene Russo, the company employs around 76 people.
The IPO was on 22/10/2021; the stock trades on NASDAQ under the ticker XLO.
What do analysts say about Xilio Therapeutics stock?
3 analysts rate the stock, the consensus is Buy (as of 08/11/2024).
The average price target is US$98.00, ranging from US$98.00 to US$98.00, with a median of US$98.00.
This is an external assessment, not a statement by Market Jury.
When does Xilio Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 50% stronger than usual.
Does Xilio Therapeutics pay a dividend?
No, Xilio Therapeutics currently does not pay a dividend.
Which stocks are comparable to Xilio Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Xilio Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Xilio Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.